AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05514197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 5000mg
Description: Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
Study NCT05514197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Rx
Description: Intravenous loading 100ml normal saline
Study NCT05675514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: The increasing number of basketball players also increases the risk of sports-related injuries. Basketball has the highest injury risk of all sports because the game is so powerful and fast moving. Myofascial release therapy; ıt is a form of manual therapy applied on the muscle fascia complex to restore optimal length, reduce pain and improve functions. It is known to be effective in providing rapid relief of pain and tissue sensitivity. By restoring the length and health of the restricted connective tissue with the myofascial release therapy, it aims to relieve pressure on pain sensitive structures such as nerves and blood vessels, as well as improves sports performance.
Study NCT05080842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC682
Description: Participants will receive AC682 by mouth daily in 28-day cycles.
Study NCT04904237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aza-Ven-allo-HSCT
Description: aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
Study NCT05324813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domain-Specific Episodic Future Thinking
Description: Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
Study NCT05324813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Domain-Specific Episodic Future Thinking
Description: Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
Study NCT05203224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: Intravenous Dornase alfa
Study NCT06043453 — intervention group
Intervention type: OTHER
Intervention: revitalization
Description: The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
Study NCT04747873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
Study NCT04747873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Stepped care procedure (see arm/group descriptions).
Study NCT04768868 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IMP7068
Description: To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
Study NCT06345898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWK002
Description: Subretinal administration of gene therapy vector JWK002 to one eye.
Study NCT05546424 — intervention group
Intervention type: BEHAVIORAL
Intervention: EMRESERVA
Description: training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
Study NCT05147649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study NCT05147649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study NCT05321771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family caregiver application of HELP principles
Description: The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
Study NCT05573347 — intervention group
Intervention type: PROCEDURE
Intervention: Rotator Cuff Repair
Description: Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
Study NCT05289024 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindful Awareness in Body-Oriented Therapy
Description: Up to 8 individually delivered clinical sessions
Study NCT05695105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush-Generated Vibration
Description: Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
Study NCT05573347 — intervention group
Intervention type: PROCEDURE
Intervention: Bone Marrow Harvest
Description: Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
Study NCT03616236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Description: Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
Study NCT03616236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will receive a referral to buprenorphine treatment in the community
Study NCT05695105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-Implant-Assisted Orthodontic Treatment
Description: Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
Study NCT06534385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air purifier
Description: Winix HEPA air purifier
Study NCT05654545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lapse prevention dialog: Boost motivation and self-efficacy
Description: In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!.
Study NCT05654545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lapse prevention dialog: Future-selves and implementation intentions
Description: In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker.
Study NCT05654545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lapse prevention dialog: Identity-related positive self-talk
Description: In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud..
Study NCT05654545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention control dialog: neutral topic
Description: The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!).
Study NCT05646758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2934 injection
Description: TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Study NCT05437237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG
Description: A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
Study NCT06234111 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Semaglutide 2.4 mg, total diet replacement, behavioural intervention
Description: Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
Study NCT04280458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intentive rehabilitation
Description: Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months.
Study NCT04280458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months.
Study NCT05480865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally
Study NCT05480865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally
Study NCT03438526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin (Circadin ®)
Description: 4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
Study NCT06529354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity Group
Description: In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
Study NCT06529354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Group
Description: In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
Study NCT04570345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor monotherapy
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy
Study NCT04570345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor monotherapy
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy
Study NCT04570345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin with P2Y12 receptor inhibitor
Description: • Drug: aspirin plus ticagrelor dual therapy during 12 months
Study NCT03438526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
Study NCT04786093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Description: Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
Study NCT04786093 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiation therapy
Description: Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
Study NCT04786093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study NCT04786093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study NCT05524480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salud en Mis Manos - Dissemination and Implementation Assistance
Description: The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
Study NCT05524480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Salud en Mis Manos- Usual Implementation Practice
Description: The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
Study NCT06535633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm: Exercise class
Description: The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
Study NCT05890430 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood draw, Urine draw
Description: Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
Study NCT06221098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral medial rectus recession
Description: release muuscle from its original insertion and backword inserted in sclera
Study NCT06465914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Study NCT06465914 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Study NCT06490172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Description: Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
Study NCT06215287 — intervention group
Intervention type: OTHER
Intervention: Physician survey
Description: Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
Study NCT05159986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week
Description: Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
Study NCT05159986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group that received exercise during eight weeks with three sessions a week
Description: The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
Study NCT05260554 — intervention group
Intervention type: DRUG
Intervention: Fosfomycin
Description: In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
Study NCT05260554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Cranberry
Description: In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
Study NCT06511375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sprint training
Description: sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
Study NCT06511375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.
Study NCT05554042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kintsugi Voice Device
Description: The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
Study NCT05490134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.